drugset
drugset / Trial / NCT05102409

An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

NCT05102409 ↗

Phase 2 Completed 56 enrolled Aldeyra Therapeutics, Inc.
Non-randomizedCrossoverQuadruple-blindTreatment

Summary

An Exploratory, Single-Center, Double-Masked, Crossover Clinical Trial to Assess Safety and Tolerability of 0.25% Reproxalap Ophthalmic Solution Compared to Xiidra® in Subjects with Dry Eye Disease in a Dry Eye Chamber

Timeline

Start
2021-09-09
Primary completion
2021-10-25
Completion
2021-10-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lifitegrast Unknown 5 % Other
Subject Reproxalap Other / unclassified 0.25 % Other

Indications

dry eye syndrome